{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:20:07Z","timestamp":1790360407112,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40120-023-00466-9","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T09:03:13Z","timestamp":1679562193000},"page":"995-1006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design of a Non-Interventional Study to Assess Neurologists\u2019 Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-9886","authenticated-orcid":false,"given":"Gustavo","family":"Saposnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"S\u00e1nchez-Benavidez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garc\u00eda-Arcelay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Franco-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Bensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Carmelingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo F.","family":"Allegri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Maurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"466_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"466_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3233\/JAD-220696","volume":"90","author":"A Villarejo-Galende","year":"2022","unstructured":"Villarejo-Galende A, Garcia-Arcelay E, Pinol-Ripoll G, et al. Quality of life and the experience of living with early-stage alzheimer\u2019s disease. J Alzheimers Dis. 2022;90:719\u201326.","journal-title":"J Alzheimers Dis"},{"key":"466_CR3","doi-asserted-by":"publisher","unstructured":"Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers Dement. 2022 https:\/\/doi.org\/10.1002\/alz.12694","DOI":"10.1002\/alz.12694"},{"key":"466_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","volume":"8","author":"J Cummings","year":"2016","unstructured":"Cummings J, Aisen PS, DuBois B, et al. Drug development in alzheimer\u2019s disease: The path to 2025. Alzheimers Res Ther. 2016;8:39.","journal-title":"Alzheimers Res Ther"},{"key":"466_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"466_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20:484\u201396.","journal-title":"Lancet Neurol"},{"key":"466_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13195-022-00971-3","volume":"14","author":"J van der Schaar","year":"2022","unstructured":"van der Schaar J, Visser LNC, Bouwman FH, et al. Considerations regarding a diagnosis of Alzheimer\u2019s disease before dementia: a systematic review. Alzheimers Res Ther. 2022;14:31.","journal-title":"Alzheimers Res Ther"},{"key":"466_CR8","doi-asserted-by":"publisher","unstructured":"Largent EA, Grill J, O'Brien K, Wolk D, Harkins K, Karlawish J. Testing for Alzheimer disease biomarkers and disclosing results across the disease continuum. Neurology. 2023 https:\/\/doi.org\/10.1212\/WNL.0000000000206891. Epub ahead of print.","DOI":"10.1212\/WNL.0000000000206891"},{"key":"466_CR9","first-page":"20","volume":"6","author":"DA Messner","year":"2019","unstructured":"Messner DA, Rabins P, Downing AC, et al. Designing trials of disease modifying agents for early and preclinical Alzheimer\u2019s disease intervention: What evidence is meaningful to patients, providers, and payers? J Prev Alzheimers Dis. 2019;6:20\u20136.","journal-title":"J Prev Alzheimers Dis"},{"key":"466_CR10","doi-asserted-by":"crossref","unstructured":"Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Rev Neurol (Paris). 2022;178:1011\u201330.","DOI":"10.1016\/j.neurol.2022.06.012"},{"key":"466_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","volume":"14","author":"SS Assun\u00e7\u00e3o","year":"2022","unstructured":"Assun\u00e7\u00e3o SS, Sperling RA, Ritchie C, Kerwin DR, Aisen PS, Lansdall C, et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:54.","journal-title":"Alzheimers Res Ther"},{"key":"466_CR12","unstructured":"US Food and Drug Administration 2021. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-new-treatment-alzheimers-disease"},{"key":"466_CR13","unstructured":"US Food and Drug Administration 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment"},{"key":"466_CR14","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"466_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"466_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:126\u201335.","journal-title":"Neurology"},{"key":"466_CR17","first-page":"221","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9:221\u201330.","journal-title":"J Prev Alzheimers Dis"},{"key":"466_CR18","unstructured":"European Medicines Agency 2021. https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-refusal-marketing-authorisation-aduhelm-aducanumab_en.pdf"},{"key":"466_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","volume":"5","author":"JS Andrews","year":"2019","unstructured":"Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials. Alzheimers Dement (N Y). 2019;5:354\u201363.","journal-title":"Alzheimers Dement (N Y)"},{"key":"466_CR20","doi-asserted-by":"publisher","first-page":"e1142","DOI":"10.1212\/WNL.0000000000200817","volume":"99","author":"E Borland","year":"2022","unstructured":"Borland E, Edgar C, Stomrud E, Cullen N, Hansson O, Palmqvist S. Clinically relevant changes for cognitive outcomes in preclinical and prodromal cognitive stages: implications for clinical Alzheimer trials. Neurology. 2022;99:e1142\u201353.","journal-title":"Neurology"},{"key":"466_CR21","first-page":"507","volume":"9","author":"S Cohen","year":"2022","unstructured":"Cohen S, Cummings J, Knox S, Potashman M, Harrison J. Clinical trial endpoints and their clinical meaningfulness in early stages of Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:507\u201322.","journal-title":"J Prev Alzheimers Dis"},{"key":"466_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: a systematic review. JAMA Neurol. 2022;79:291\u2013304.","journal-title":"JAMA Neurol"},{"key":"466_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12911-016-0377-1","volume":"16","author":"G Saposnik","year":"2016","unstructured":"Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Mak. 2016;16:138.","journal-title":"BMC Med Inform Decis Mak"},{"key":"466_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.trci.2019.05.001","volume":"5","author":"R Mauricio","year":"2019","unstructured":"Mauricio R, Benn C, Davis J, et al. Tackling gaps in developing life-changing treatments for dementia. Alzheimers Dement (N Y). 2019;5:241\u201353.","journal-title":"Alzheimers Dement (N Y)"},{"key":"466_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.592302","volume":"11","author":"JE Galvin","year":"2021","unstructured":"Galvin JE, Aisen P, Langbaum JB, et al. Early stages of Alzheimer\u2019s disease: evolving the care team for optimal patient management. Front Neurol. 2021;11: 592302.","journal-title":"Front Neurol"},{"key":"466_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.997277","volume":"9","author":"G Saposnik","year":"2022","unstructured":"Saposnik G, Ismail Z, Rivard AM, et al. Decision making under uncertainty in the diagnosis and management of Alzheimer\u2019s Disease in primary care: A study protocol applying concepts from neuroeconomics. Front Med (Lausanne). 2022;9: 997277.","journal-title":"Front Med (Lausanne)"},{"key":"466_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fneur.2017.00065","volume":"8","author":"G Saposnik","year":"2017","unstructured":"Saposnik G, Sempere AP, Prefasi D, et al. Decision-making in Multiple Sclerosis: The role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). Front Neurol. 2017;8:65.","journal-title":"Front Neurol"},{"key":"466_CR28","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.03.005","volume":"27","author":"LA Sposato","year":"2018","unstructured":"Sposato LA, Stirling D, Saposnik G. Therapeutic decisions in atrial fibrillation for stroke prevention: The role of aversion to ambiguity and physicians\u2019 risk preferences. J Stroke Cerebrovasc Dis. 2018;27:2088\u201395.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"466_CR29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40120-022-00366-4","volume":"11","author":"G Saposnik","year":"2022","unstructured":"Saposnik G, Camacho A, D\u00edaz-Ab\u00f3s P, et al. Therapeutic decision-making under uncertainty in the management of spinal muscular atrophy: results from DECISIONS-SMA study. Neurol Ther. 2022;11:1209\u201319.","journal-title":"Neurol Ther"},{"key":"466_CR30","doi-asserted-by":"crossref","unstructured":"Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France. Rev Neurol (Paris). 2022;178:999\u20131010.","DOI":"10.1016\/j.neurol.2022.08.002"},{"key":"466_CR31","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1503\/cmaj.081231","volume":"182","author":"A Kitson","year":"2010","unstructured":"Kitson A, Straus SE. The knowledge-to-action cycle: identifying the gaps. CMAJ. 2010;182:E73\u20137.","journal-title":"CMAJ"},{"key":"466_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103404","volume":"58","author":"G Saposnik","year":"2022","unstructured":"Saposnik G, Andhavarapu S, Fern\u00e1ndez \u00d3, et al. Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study. Mult Scler Relat Disord. 2022;58: 103404.","journal-title":"Mult Scler Relat Disord"},{"key":"466_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010716-104952","volume":"57","author":"KL Lavoie","year":"2017","unstructured":"Lavoie KL, Rash JA, Campbell TS. Changing provider behavior in the context of chronic disease management: focus on clinical inertia. Annu Rev Pharmacol Toxicol. 2017;57:263\u201383.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"466_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pec.2009.10.030","volume":"80","author":"MC Politi","year":"2010","unstructured":"Politi MC, L\u00e9gar\u00e9 F. Physicians\u2019 reactions to uncertainty in the context of shared decision making. Patient Educ Couns. 2010;80:155\u20137.","journal-title":"Patient Educ Couns"},{"key":"466_CR35","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/MLR.0000000000000157","volume":"52","author":"BA Cunningham","year":"2014","unstructured":"Cunningham BA, Bonham VL, Sellers SL, et al. Physicians\u2019 anxiety due to uncertainty and use of race in medical decision making. Med Care. 2014;52:728\u201333.","journal-title":"Med Care"},{"key":"466_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103389","volume":"57","author":"G Saposnik","year":"2022","unstructured":"Saposnik G, Andhavarapu S, Fern\u00e1ndez \u00d3, et al. Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Mult Scler Relat Disord. 2022;57: 103389.","journal-title":"Mult Scler Relat Disord"},{"key":"466_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hec.1697","volume":"21","author":"EW de Bekker-Grob","year":"2012","unstructured":"de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21:145\u201372.","journal-title":"Health Econ"},{"key":"466_CR38","doi-asserted-by":"crossref","unstructured":"Cohen CI, Reisberg B, Yaffee R. Global cognitive trajectory patterns in Alzheimer's disease. Int Psychogeriatr. 2022 Epub ahead of print.","DOI":"10.1017\/S1041610222000047"},{"key":"466_CR39","doi-asserted-by":"publisher","first-page":"e575","DOI":"10.1016\/S2666-7568(22)00191-X","volume":"3","author":"PB Adkins-Jackson","year":"2022","unstructured":"Adkins-Jackson PB, Belsky DW. Alzheimer\u2019s disease risk biomarkers: progress and challenges. Lancet Healthy Longev. 2022;3:e575\u20136.","journal-title":"Lancet Healthy Longev"},{"key":"466_CR40","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1038\/s41598-021-83126-y","volume":"11","author":"N Roberto","year":"2021","unstructured":"Roberto N, Portella MJ, Marqui\u00e9 M, et al. Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis. Sci Rep. 2021;11:6448.","journal-title":"Sci Rep"},{"key":"466_CR41","unstructured":"Orme BK. Getting started with conjoint analysis: Strategies for product design and pricing research. Research Publishers, LLC; 1st edition, 2005."},{"key":"466_CR42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40120-022-00423-y","volume":"12","author":"G Dranitsaris","year":"2023","unstructured":"Dranitsaris G, Zhang Q, Quill A, et al. Treatment preference for Alzheimer\u2019s disease: A multicriteria decision analysis with caregivers, neurologists, and payors. Neurol Ther. 2023;12:211\u201327.","journal-title":"Neurol Ther"},{"key":"466_CR43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jval.2015.10.011","volume":"19","author":"A M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher A, Johnson FR, Yang JC, Happich M, Belger M. Do you want to hear the bad news? the value of diagnostic tests for Alzheimer\u2019s disease. Value Health. 2016;19:66\u201374.","journal-title":"Value Health"},{"key":"466_CR44","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jval.2019.03.022","volume":"22","author":"FR Johnson","year":"2019","unstructured":"Johnson FR, DiSantostefano RL, Yang JC, Reed SD, Streffer J, Levitan B. Something is better than nothing: the value of active intervention in stated preferences for treatments to delay onset of Alzheimer\u2019s disease symptoms. Value Health. 2019;22:1063\u20139.","journal-title":"Value Health"},{"key":"466_CR45","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/0272989X211040815","volume":"42","author":"D Drewniak","year":"2022","unstructured":"Drewniak D, Brandi G, Buehler PK, et al. Key factors in decision making for ECLS: a binational factorial survey. Med Decis Making. 2022;42:313\u201325.","journal-title":"Med Decis Making"},{"key":"466_CR46","doi-asserted-by":"crossref","unstructured":"Sydenham RV, Jarb\u00f8l DE, Hansen MP, Justesen US, Watson V, Pedersen LB. Prescribing antibiotics: Factors driving decision-making in general practice. A discrete choice experiment. Soc Sci Med. 2022;305:115033.","DOI":"10.1016\/j.socscimed.2022.115033"},{"key":"466_CR47","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.spinee.2020.11.010","volume":"21","author":"N Schneider","year":"2021","unstructured":"Schneider N, Fisher C, Glennie A, et al. Lumbar degenerative spondylolisthesis: factors associated with the decision to fuse. Spine J. 2021;21:821\u20138.","journal-title":"Spine J"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00466-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00466-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00466-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:50:14Z","timestamp":1684399814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00466-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00466-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}